Abstract
Pancreaticobiliary cancers are a group of malignancies affecting the pancreas and biliary tract and are often associated with poor prognosis. Existing treatment strategies for these malignancies are limited. However, with the development of more advanced genomic analysis techniques, several mutations have been identified that may be targeted for the development of novel treatments. Key targets of interest include DNA damage repair (DDR) pathways for both pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) as well as isocitrate dehydrogenase 1 (IDH1) and fibroblast growth factor receptor (FGFR) in BTC and mismatch repair (MMR) genes and germline mutations in PDAC. Additionally, a better understanding of the immune microenvironment of pancreatic and biliary cancers has revealed cell types and signaling pathways that may be leveraged for treatment. This includes PD-L1 and CTLA-4 immune checkpoints, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and dendritic cells (DCs). Together, targeted agents and immunotherapy strategies have the potential to significantly improve the existing treatment landscape for pancreaticobiliary cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Society of Clinical Oncology Educational Book
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
